2018 / 06

Next Paper
DOI: 10.24075/brsmu.2018.092
Copyright: © 2018 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

OPINION

Development of liposomal drug formulations: quality attributes and methods for quality control

Melnikova EV , Goryachev DV , Chaplenko AA , Vodyakova MA , Sayfutdinova AR , Merkulov VA
About authors

Scientific center for expert evaluation of medicinal products of the Ministry of health of the Russian Federation, Moscow

Correspondence should be addressed: Alexander A. Chaplenko
Shchukinskaya, 6 bl. 1, Moscow, 127051; ur.dempxe@oknelpahc

Received: 2018-06-29 Accepted: 2018-09-02 Published online: 2018-12-31
|
  1. Krasnopolsky YuM, Stepanov AE, Shvets VI. Technological aspects of production of liposomal preparations under GMP conditions. Biofarm J. 2009; 3: 18–29.
  2. Baryshnikov AYu. Nanostructured liposomal systems as a means of delivery of anticancer drugs. Vestnik RAMS. 2012; 3: 23–31.
  3. Hobbs SK, Monsky WL, Yuan F. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998; 95: 4607–4612.
  4. Shvets IV, Kaplun AP, Krasnopolsky YuM. et al. From liposome seventies to nanobiotechnology XXI century. Ross nanotechnologies. 2008; 3 (11–12): 6–20.
  5. Love WG, Amos N, Kellaway IW, Williams BD. Specific accumulation of cholesterol-rich liposomes in the inflammatory tissue of rats with adjuvant arthritis. Ann Rheum Dis. 1990; 49 (8): 611–614.
  6. Chekhonin VP, Baklaushev VP, Yusubalieva GM. et al. Modeling and immunohistochemical analysis of glioma C6. Cell technol in biol and med. 2007; 2: 65–73.
  7. Chekhonin VP, Zhirkov YuA, Gurina OI. et al. The Pegylated immunoliposome specific to astrocytes. Dokl. RAN. 2003; 391 (6): 1–7.
  8. Chekhonin VP, Gurina OI, Dmitrieva TB. Monoclonal antibodies to neurospecific proteins. M.: Medicine, 2007; 344.
  9. Errede M, Benagiano V, Girolamo F et al. Differential expression of connexin43 in foetal, adult and tumour-associated human brain endothelial cells. Histochem J. 2002; 34: 265–271.
  10. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale and clinical applications, existing and potential. Int J Nanomedicine. 2006; 1 (3): 297–315.
  11. Felnerova D, Viret J-F, Gluck R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol. 2004; 15: 518–529.
  12. Barenholz Y. Liposome application: problems and prospects. Curr Opin Colloid Interface Sci. 2001; 6: 66–77.
  13. Vasir JK, Reddy MK, Labhasetwar VD. Nanosystems in drug targeting: opportunities and challenges. Curr Nanoscience. 2005; 1 (1): 47–64.
  14. Basu MK. Liposomal delivery of antileishmanial agents. J Applied Research. 2005; 5 (1): 221–236.
  15. Zurbriggen R, Amacker M, Krammer AR. Immunopotentiating reconstituted influenza virosomes. In: G. Gregoriadis eds. Liposome technology. 3rd edn. Vol. I. Liposome preparation and related techniques. New York: Informa Healthcare USA, 2007; 85–96.
  16. Fang J, Sawa T, Maeda H. Factors and mechanism of «epr» effect and the enhanced antitumor effects of macromolecular drugs including smancs. Adv Exp Med Biol. 2003; 519: 29–49.
  17. Greish K, Fang J, Inutsuka T. et al. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet. 2003; 42: 1089–1105.
  18. Maeda H. The enhanced permeability and retention (epr) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41: 189–207.
  19. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urologic Oncology: Seminars and Original Investigations. 2008; 26: 57–64.
  20. Lantsova AV. Creation and biopharmaceutical study of liposomal dosage forms of anticancer drugs derived from nitrosourea. Abstract dis kand farm. sciences. Moscow, 2006; 173.
  21. Lantsova AV, Oborotova NA, Peretolchina NM et al. Comparative study of the antitumor activity of the liposomal dosage forms of drugs, derivatives of nitrozomocevina. Sibirs oncologist J. 2005; 2 (14): 25–29.
  22. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002; 2 (10): 750–763.
  23. Tolcheva EV. Design of immunoliposomes and study of immunoliposomal form of anticancer drug doxorubicin. Abstract dis kand Biol sciences. M., 2007; 109 р.
  24. Sokolova DV, Tazina EV, Kortava MA. et al. Anti-CD40 and anti- HLA-DR immunoliposomal form doxorubicin: technology of production and antigen specificity in vivo. Ross biotherapeutic J. 2010; 9 (2): 90.
  25. Sokolova DV, Tazina EV, Kortava MA et al. Anti-MUC1 immunoliposomal form of doxorubicin: technology of production and antigen specificity in vitro. Ross biotherapeutic J. 2010; 9 (3): 21.
  26. Khugaeva OV, Kortava MA, Sokolova DV et al. Receiving liposomal mitoxantrone/materials of the IX all-Russian. scientific.- prakt. Conf. "Domestic anticancer drugs". Ross biotherapeutic J. 2010; 9 (2): 91.
  27. Nasonov EL. Prospects of rituximab use in autoimmune diseases of a person. Rus Med J. 2007; 15 (26): 1–6.
  28. Sokolova DV. Immunoliposomal constructions of doxorubicin and models for their preclinical study. Abstract dis kand Biol sciences. M., 2011; 122.
  29. Kawakami S, Fumoto S, Nishikawa M et al. In vivo gene delivery to the liver using novel galactosylated cationic liposomes. Pharmaceuttic Research. 2000; 17 (3): 306–313.
  30. Dass CR, Choong PFM. Targeting of small molecule anticancer drugs to the tumor and its vasculature using cationic liposomes: lessons from gene therapy. Cancer Cell Int. 2006; 6 (17): 1–9.
  31. Ponce AM, Wright A, Dewhirst MW, Needham D. Targeted bioavailability of drugs by triggered release from liposomes. Future Lipidol. 2006; 1 (1): 25–34.
  32. Jain S, Mishra V, Singh P et al. RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int J Pharm. 2003; 261 (1–2): 43–55.
  33. Qin J, Chen D, Hu H et al. Surface modification of RGD-liposomes for selective drug delivery to monocytes/Neutrophils in brain. Chem Pharm Bull. 2007; 55 (8): 1192–1197.
  34. Campbell RB, Fukumura D, Brown EB et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 2002; 62: 6831–6836.
  35. Ambegia E, Ansell S, Cullis P et al. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta. 2005; 1669 (2): 155–163.
  36. Dass CR. Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumor vasculature. Int J Pharm. 2003; 267 (1–2): 1–12.
  37. Tazina EV, Mescheryakova VV, Ignatieva EV et al. Biopharmaceutical studies of temperature-sensitive liposomal formulations of doxorubicin. Ross biotherapeutic J. 2009; 1 (8): 40–47.
  38. Huang Z, Szoka FC. Bioresponsive liposomes and their use for macromolecular delivery. In: G. Gregoriadis eds. Liposome technology. 3rd edn. Vol. I. Liposome preparation and related techniques. New York: Informa Healthcare USA, 2007; 165–196.
  39. Chekhonin VP, Zhirkov YuA, Aglow NV et al. Directed transport of drugs using liposomes. Vestn RAMS. 2004; 5: 42–47.
  40. Wu D, Pardridge WM. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci USA. 1999; 96: 254–259.
  41. Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA. 2000; 97 (13): 7567–7572.
  42. Pal A, Ahmad A, Khan S et al. Systemic delivery of RafsiRNA using cationic liposomes silences Raf in xenograft model of human prostate cancer. Int J Oncol. 2005; 26 (4): 1087–1091.
  43. Omidi Y, Barar J, Akhtar S. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray. Curr Drug Del. 2005; 2 (4): 429–441.
  44. Oliveira S, Storm G, Schiffelers. Targeted delivery of siRNA. J Biomed Biotechnol. 2006; 2006: 1–7.
  45. Miyazaki M, Obata Y, Abe K et al. Gene transfer using nonviral delivery systems. Perit Dial Int. 2006; 26: 633–640.
  46. Aguilar JC. Vaccine adjuvants revisited. Vaccine. 2007; 25: 3752– 3762.
  47. Perrie Y, Frederik PM, Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine. 2001; 19: 3301–3310.
  48. Pharmaceutical development: concept and practical recommendations. Scientific-practical guide for the pharmaceutical industry / ed. by Bykov SN, Vasilenko IA, Demina NB, Shokhin IE, Novojilov OV, Meshkovsky AP, Spitskov ORM. Pero, 2015; 472 р.
  49. Lu D, Hickey AJ. Liposomal dry powders as aerosols for pulmonary delivery of proteins. AAPS Pharm Sci Tech. 2005; 6 (4): 641–648.
  50. De Lima MCP, Simoes S, Pires P et al. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv Drug Del Rev. 2001; 47: 277–294.